Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

MANTA Closure Device for large-bore arteriotomy closure: Is It Safe?

 Courtesy of Dr. Agustín Vecchia. 

MANTA Closure Device for large-bore arteriotomy closureThe number of transcatheter aortic valve replacements (TAVR) and the placement of aortic endoprosthesis and ventricular assist devices, among others, have grown exponentially worldwide in the last few years. In a short time, many of these procedures will surely become the new standard of care. Logically, this growth comes hand in hand with a progressively more frequent use of large-bore catheters and a higher need for closure devices for the safe performance of these procedures.

 

The following prospective, multicentre study was conducted in three European institutions and was aimed at assessing the safety and efficacy of the MANTA vascular closure device system, designed for 10- to 25-Fr-arteriotomy closure. This device contains a closure unit consisting of polylactic acid (intraarterial toggle), a bovine collagen (extravascular) pad, a nonresorbable polyester suture connecting both, and a stainless steel (nonresorbable) suture lock.

 

The study enrolled 50 patients with a mean age of 79.5 years, who underwent the following:

  • complex coronary angioplasty,
  • ballon aortic valvuloplasty, or
  • transcatheter aortic valve replacement with large-bore catheters (12 to 19 French, i.e., 4 to 6.33 mm).

 

MANTA closure was performed by 9 different operators. Almost the whole group (47 out of 50 patients) underwent TAVR. The mean time to hemostasis with the MANTA device was 2 minutes, 23 seconds.

 

One patient experienced a major vascular complication that required a covered stent and subsequent surgical correction (this patient required emergency surgery for an incorrectly-placed TAVR device). One patient experienced minor bleeding (VARC-2) and one patient experienced a pseudoaneurism. Mortality at 30 days was 8% (n = 4); there were no device-related mortality events. Five patients presented subcutaneous bruising that did not require treatment. The control angiography conducted after the procedure showed patency in the femoral artery in all patients.

 

Conclusion

The authors conclude that the MANTA device demonstrates safety and rapid hemostasis for large-bore arteriotomy closure.

 

Editorial

The importance of this study lies in the fact that most vascular complications observed in large-bore arteriotomies (regardless of the procedure) derive from closure flaws, and MANTA offers the first alternative in that sense.

 

Something to be highlighted is the fact that, although none of the 9 operators in this study had previous experience with the device, this was placed correctly in all patients (in a clinical study context), with acceptable rates of both minor and major complications. This is particularly surprising, taking into account the complication rates observed in recent studies such as “CONTROL” (Closure Device in Transfemoral Aortic Valve Implantation), which enrolled 944 patients undergoing TAVR and compared Prostar XL vs. Perclose Proglide (Abbott Vascular, Redwood City, California). In that case, the rate of major and minor bleeding, according to the VARC classification, was 7.4% and 14.8%, respectively, for patients in the Prostar arm, and 1.9% and 18%, respectively, for patients in the Proglide arm.

 

Courtesy of Dr. Agustín Vecchia. Buenos Aires German Hospital, Argentina.

 

Original title: Percutaneous Plug-Based Arteriotomy Closure Device for Large-Bore Access A Multicenter Prospective Study.

Reference: DOI: 10.1016/j.jcin.2016.12.028 JACC Cardiovascular Interventions.

Authors: Nicolas M. Van Mieghem, MD, PHD, Azeem Latib, MD, Jan van der Heyden, MD, PHD, Lennart van Gils, MD, Joost Daemen, MD, PHD, Todd Sorzano, Jurgen Ligthart, RT, Karin Witberg, CCRN, Thom de Kroon, MD, Nathaniel Maor, Antonio Mangieri, MD, Matteo Montorfano, MD, Peter P. de Jaegere, MD, PHD, Antonio Colombo, MD, Gary Roubin, MD, PHD.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...